Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23402376 | 0.78 | ALDH1A1 (0.37) | KDM4E | |
| SCHEMBL28625759 | 0.77 | KDM4E (0.30) | KDM4ECYP1A2CYP2D6ALOX15TDP1 | |
| SCHEMBL23399295 | 0.74 | — | — | |
| SCHEMBL6183796 | 0.69 | — | — | |
| SCHEMBL2349675 | 0.68 | MAPT (0.37) | KDM4E | |
| SCHEMBL10977291 | 0.64 | CDK4 (0.35) | — | |
| SCHEMBL1764531 | 0.61 | — | — | |
| SCHEMBL5203482 | 0.61 | CYP19A1 (0.42) | — | |
| SCHEMBL24309056 | 0.60 | NPC1 (0.41) | KDM4E | |
| SCHEMBL208629 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732464-B2 | Heterocyclic substituted 4-(aminomethyl)-piperidine benzamides as 5HT4-antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2010-06-08 | — | — | US | disclosed |
| US-7732464-B2 | Heterocyclic substituted 4-(aminomethyl)-piperidine benzamides as 5HT4-antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2010-06-08 | — | — | US | disclosed |
| US-20070197600-A1 | Heterocyclic substituted 4-(aminomethyl)-piperidine benzamides as 5ht4-antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2007-08-23 | — | — | US | disclosed |
| US-20070197600-A1 | Heterocyclic substituted 4-(aminomethyl)-piperidine benzamides as 5ht4-antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2007-08-23 | — | — | US | disclosed |
| WO-2005003124-A1 | HETEROCYCLIC SUBSTITUTED 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES AS 5HT4-ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197600-A1 | Heterocyclic substituted 4-(aminomethyl)-piperidine benzamides as 5ht4-antagonists | HTR4, HTR2B, HTR5A | KDM4E 446/4885CYP1A2 438/4885CYP2D6 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.